In a remarkable scientific breakthrough that researchers are calling a ‘eureka moment,’ a team at the University of Cambridge has potentially turned a cheap painkiller into a new weapon to fight against cancer metastasis – aspirin. Aspirin, a common, over-the-counter medication has long been known for its anti-inflammatory and pain-relieving properties. However, this new research suggests it may also play a crucial role in preventing cancer from spreading throughout the body by activating the immune system. This discovery builds upon years of observational studies linking low-dose aspirin to reduced metastasis in some cancers.
Understanding Metastasis: The Driving Force Behind Cancer Deaths
The vast majority of cancer-related deaths – approximately 90% – occur not because of the primary tumour itself, but because of metastasis. This is the process by which cancer cells break away from the original tumour and travel through the bloodstream or lymphatic system to set up secondary tumours in distant organs like the lungs, liver, brain, and bones. Recent advances in immunotherapy, which have tapped into the power of the immune system to fight cancer, have shown promise in treating established metastatic disease. The new research on aspirin suggests that this readily available medication may be one such therapy that could utilize the immune system to tackle cancer metastasis.
Unraveling the Mechanism: How Aspirin Impacts the Immune System
The Cambridge researchers have delved into understanding how the immune system interacts with metastasizing cancer cells. They hypothesized that lone cancer cells, having detached from the primary tumour, are more vulnerable to attack by the body’s T-Cells than cancer cells within the larger, initially established tumour mass. This is because the tumour microenvironment often suppresses the immune system, allowing cancer cells to evade detection and destruction.
To investigate this hypothesis, the researchers conducted a series of experiments in mice, screening hundreds of genes to identify those that play a role in cancer metastasis. One gene, which makes a protein called ARHGEF1, stood out. Mice lacking this gene exhibited significantly less metastasis of various primary cancers to the lungs and liver.
This finding led the researchers to investigate the function of ARHGEF1. They discovered that this protein suppresses T-cells, a critical type of immune cell responsible for recognizing and killing cancer cells. T cells patrol the body, scanning for abnormal cells. When they encounter a cell displaying cancer-specific antigens on its surface, they become activated and launch an attack, destroying the cancerous cell.
However, ARHGEF1 interferes with this process by inhibiting T-cell activation. By suppressing T cells, ARHGEF1 effectively shields cancer cells from attack by T-cells, allowing them to spread and establish metastases.
Read More: Rectal Cancer Vanishes After Immunotherapy Trial, Now Classified as FDA Breakthrough Therapy
The “Eureka Moment”: Aspirin’s Unexpected Connection
The researchers then sought to identify a way to target ARHGEF1 and restore T-cell function. Through a process of elimination, they discovered that thromboxane A2 (TXA2), a clotting factor, activates ARHGEF1 when it exposes T-cells. TXA2 is already well-known for its role in blood clotting and its link to aspirin. TXA2 is produced by platelets, small cells in the blood that help form clots to stop bleeding.
Aspirin slows down the production of TXA2, reducing platelet aggregation and preventing blood clots. This is why aspirin is commonly used to prevent heart attacks and strokes, by thinning the blood. The researchers realized that aspirin‘s ability to inhibit TXA2 production could also have an impact on cancer metastasis. By reducing TXA2 levels, aspirin could prevent ARHGEF1 from being activated, thereby releasing T-cells from suppression and allowing them to attack cancer cells.
To test this hypothesis, the researchers conducted experiments in mice with melanoma, a type of skin cancer that is prone to metastasis. They found that mice treated with aspirin had a significantly lower frequency of metastases compared to control mice. TXA2’s release of T-cells from suppression caused this effect, confirming that the immune system mediates aspirin’s anti-metastatic activity.
Implications for Cancer Treatment and Prevention
Aspirin is a widely available, cheap medication with a well-established safety profile. Its potential to prevent cancer metastasis by activating the immune system could completely change cancer therapy, particularly for patients at high risk of recurrence. One potential application of aspirin is as an adjuvant therapy following surgery or other treatments for early-stage cancer. By preventing the formation of micrometastases, aspirin could reduce the risk of relapse and improve long-term survival.
Another potential application is in combination with immunotherapy. By releasing T-cells from suppression, aspirin could enhance the effectiveness of immunotherapeutic agents, leading to better outcomes for patients with advanced cancer. Dr. Jie Yang, who led the Cambridge study, emphasized the potential for aspirin or other drugs targeting this pathway to be more accessible globally than antibody-based therapies. This has the potential to significantly impact cancer care in low and middle-income countries, where limited access restricts expensive treatments.
Cautions and Considerations
While the findings on aspirin and cancer metastasis are promising, it is important to exercise caution and consult with a healthcare professional before taking aspirin regularly for cancer prevention. Aspirin can cause serious side effects in some individuals, including bleeding, stomach ulcers, and allergic reactions.
The risk of these side effects must be weighed against the potential benefits of aspirin in preventing cancer metastasis. Clinical trials are underway to determine the optimal dose of aspirin for cancer prevention and to identify individuals who are most likely to benefit from this therapy. These trials will also help to assess the long-term safety of aspirin use in cancer patients.
Future Directions
The Cambridge researchers are now collaborating with Professor Ruth Langley, who is leading the Add-Aspirin clinical trial, to determine if aspirin can stop or delay the recurrence of early-stage cancers. This trial is enrolling patients with breast, bowel, and prostate cancers who have already undergone standard treatments.The results of the Add-Aspirin trial will provide valuable information on the efficacy and safety of aspirin in preventing cancer recurrence.
These findings will help to guide clinical practice and inform the development of new strategies for cancer prevention and treatment. In addition to clinical trials, future research will focus on identifying other drugs that can target the TXA2-ARHGEF1 pathway and enhance T-cell function. These drugs may offer a more targeted and effective approach to preventing cancer metastasis with fewer side effects than aspirin.
Conclusion
The discovery that aspirin can potentially prevent the spread of some cancers by stimulating the immune system is a significant step forward in the fight against cancer. A study of incident cancers during randomised controlled trials determined that aspirin prevents distant metastasis. Although further research must fully explain this finding’s implications, it offers a promising new avenue for developing more effective and accessible cancer therapies.
Read More: Child Who Underwent CAR-T Cancer Therapy Remains Disease-Free After 18 Years